NEW YORK, N.Y., April 1, 2016 (SEND2PRESS NEWSWIRE) -- Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).
NEW YORK, N.Y., Dec. 7, 2015 (SEND2PRESS NEWSWIRE) -- Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.
LOS ANGELES, Calif., Aug. 14, 2015 (SEND2PRESS NEWSWIRE) -- A Los Angeles County Superior Court jury this month handed Hennessy Industries, Inc. as successor to AMMCO Tools, Inc., its first-ever loss in an asbestos-exposure lawsuit despite the defendant company's self-assurances that the grieving family of an Army veteran and automotive parts store owner who died of mesothelioma had no chance of winning, victorious plaintiffs' law firm Weitz and Luxenberg, P.C., today announced.
NEW YORK, N.Y., April 7, 2015 (SEND2PRESS NEWSWIRE) -- Weitz and Luxenberg, P.C., announced it is accepting cases of congenital heart defects and cleft facial abnormalities in children whose mothers took the prescription drug Zofran during pregnancy to relieve symptoms of morning sickness.
